ESR1 and breast carcinoma: Notably, many patients that relapse while on tamoxifen therapy retain expression of PR, underscoring the clinical significance of considering PRs as potentially acting independently of ER in the context of breast cancer progression during estrogen ablation (that is, PR expression is most often used clinically as a measure of ER function) [72,73].